An Irish company that develops treatments for inflammatory diseases has been sold in one of the largest deals in Irish biotech history.
Swiss healthcare company, Roche, has acquired Inflazome for an up front payment of €380 million.
The company was founded in 2016 following a research collaboration between the University of Queensland and Trinity College, and is based in Dublin.
Professor Luke O'Neill, who co-founded Inflazome, says it is a great day for the company.
"Roche can now take out drug and bring it to the clinic which is tremendously exciting. We're talking about Alzheimer's, Parkinson's, Cardiovascular disease- all these inflammatory diseases seem to involve one thing that goes wrong in your body.
"We have a drug that can correct it so it's a great day for the company."
